Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. TransThera Sciences (Nanjing)'s General and Admin. Expense for the
six
months ended in Dec. 2025 was HK$30.17 Mil.
Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 was HK$60.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransThera Sciences (Nanjing) General and Admin. Expense Chart
TransThera Sciences (Nanjing) General and Admin. Expense Calculation
General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.
General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$60.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a General and Admin. Expense of HK$60.19 Mil mean?
TransThera Sciences (Nanjing) (HKSE:02617) has a General and Admin. Expense of HK$60.19 Mil as of Dec. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on TransThera Sciences (Nanjing) and its competitors.
Is TransThera Sciences (Nanjing)'s General and Admin. Expense too high?
TransThera Sciences (Nanjing)'s current General and Admin. Expense is HK$60.19 Mil. Overall, TransThera Sciences (Nanjing) has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does TransThera Sciences (Nanjing)'s General and Admin. Expense compare to VRTX and REGN?
TransThera Sciences (Nanjing)'s General and Admin. Expense of HK$60.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on TransThera Sciences (Nanjing) and its competitors. TransThera Sciences (Nanjing)'s current General and Admin. Expense is HK$60.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransThera Sciences (Nanjing) stock overvalued right now?
TransThera Sciences (Nanjing) (HKSE:02617) has a current General and Admin. Expense of HK$60.19 Mil. The current General and Admin. Expense is HK$60.19 Mil. TransThera Sciences (Nanjing)'s overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For TransThera Sciences (Nanjing) (HKSE:02617), the current General and Admin. Expense is HK$60.19 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its core Product Tinengotinib is a multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
9GF Score
Get the complete analysis for HKSE:02617
General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02617 has been successfully added to your 
